Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.
about
Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisEffect of gastrointestinal resection on sunitinib exposure in patients with GIST.Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumoursOptimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour.A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment.Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).The role of imatinib plasma level testing in gastrointestinal stromal tumor.Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase.Long-term efficacy of imatinib for treatment of metastatic GIST.Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients.Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients.Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?Prolonging Gastrointestinal-Stromal-Tumor-free life, an optimal suggestion of imatinib intervention ahead of operation
P2860
Q26800005-82A4EDAF-4EB1-4301-ACFF-DC2E796D5E3CQ34048307-CC6EE534-DC4C-406B-81FB-6A3141EFF331Q34300784-CC7164FA-5899-48B4-A231-8FE1EFE55523Q34339623-56F54DAF-B069-4B91-924F-4C6E35C4E768Q36180074-1A098859-F8F8-4531-9934-CD255A1BD8EFQ36407123-6DB18873-B718-4844-B3A6-5C6122D4CFB3Q36729934-D303A287-8475-48D7-825C-ED79618E37DDQ37301465-23FE7001-CD00-4AB8-8722-CBD00E7A2288Q37504935-426905F4-64A6-4722-ABFC-FC5445BD5D59Q37606055-50F65E41-B708-4E32-800C-1913572BFA3AQ37729245-347FB233-2AA2-471D-A6D8-C824D514EFC3Q37731289-B3133076-5B89-422C-9758-C24E8C9B8AD4Q37747750-EF028B4B-AD12-4A11-8C64-5AAA56C4B9E6Q37817815-CBF6853F-CECC-4776-9471-36BCDD2FB3AEQ37862942-B722231C-C85F-4DC9-98A5-71456A315479Q38090470-B3E8DF3C-DBE7-44A2-8903-5D1AB7F884CEQ38391227-CD923A8A-13EE-48FF-8122-F44D232B7780Q38729029-38127A90-3F85-45C0-9CE4-14C1E848C355Q40721053-0D797508-29FE-44E2-BA9A-79BB60A1437CQ41763725-A33C07B4-C214-40F0-A55B-6BCDB8672155Q42556614-5CE9D87F-C6B7-4407-AF36-CCC467267024Q47847397-2D5DC74A-EB15-49A1-9CA0-99582C91637FQ48152547-2877E93D-EF2F-4886-B62B-BD870EC5297BQ48177111-933B2AC6-3DD9-452D-AFE5-BBD8BD618BE7Q48278939-7EC80A86-C984-4E3A-B160-452CF38B5D37Q58582206-8632EF3C-C51E-4898-9976-2A03839153BA
P2860
Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Cross-sectional study of imati ...... ction on exposure to imatinib.
@en
Cross-sectional study of imati ...... ction on exposure to imatinib.
@nl
type
label
Cross-sectional study of imati ...... ction on exposure to imatinib.
@en
Cross-sectional study of imati ...... ction on exposure to imatinib.
@nl
prefLabel
Cross-sectional study of imati ...... ction on exposure to imatinib.
@en
Cross-sectional study of imati ...... ction on exposure to imatinib.
@nl
P2093
P356
P1476
Cross-sectional study of imati ...... ction on exposure to imatinib.
@en
P2093
Baek-Yeol Ryoo
Byung Woog Kang
Changhoon Yoo
Heung-Moon Chang
Jae-Lyun Lee
Min-Hee Ryu
Mo Youl Beck
Shin-Kyo Yoon
Tae Won Kim
Yoon-Koo Kang
P304
P356
10.1200/JCO.2009.26.5785
P407
P577
2010-02-22T00:00:00Z